Ignite Creation Date:
2025-12-25 @ 2:46 AM
Ignite Modification Date:
2026-01-08 @ 2:03 PM
Study NCT ID:
NCT00582933
Status:
COMPLETED
Last Update Posted:
2016-02-01
First Post:
2007-12-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2001-05
Start Date Type:
None
Primary Completion Date:
2008-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-04
Completion Date Type:
ACTUAL
First Submit Date:
2007-12-21
First Submit QC Date:
None
Study First Post Date:
2007-12-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2015-12-22
Results First Submit QC Date:
None
Results First Post Date:
2016-02-01
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-12-22
Last Update Post Date:
2016-02-01
Last Update Post Date Type:
ESTIMATED